文献速递物质与行为成瘾

GLP-1与酒精相关行为:临床前研究启示

GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
PubMed 文献 · Biol Psychiatry · 2026-07-15

临床前研究显示,短效(艾塞那肽/Ex4)和长效(利拉鲁肽、度拉糖肽、司美格鲁肽)GLP-1受体激动剂可减少雄性动物酒精摄入、饮酒动机及复发样行为,并减弱酒精奖赏效应;但胃排空改变、恶心和应激增强也可能参与其中。

要点

  • 短效GLP-1R激动剂Ex4减少雄性动物酒精摄入、动机和复发样行为。
  • 长效GLP-1R激动剂减少雄性及雌性动物酒精消费行为。
  • 短效和长效GLP-1R激动剂减弱雄性小鼠酒精奖赏效应。

核心结论

  • 临床前研究提示GLP-1R激动剂可能用于酒精使用障碍(AUD)治疗。
  • GLP-1R激动剂可能通过减弱酒精奖赏效应减少酒精摄入。

研究设计与样本

  • 综述临床前研究,涉及短效(Ex4)和长效(利拉鲁肽、度拉糖肽、司美格鲁肽)GLP-1R激动剂。

主要发现

  • Ex4全身治疗减少雄性动物酒精摄入、饮酒动机和复发样行为。
  • 长效GLP-1R激动剂减少雄性或雌性动物酒精消费行为。
  • 短效和长效GLP-1R激动剂减弱雄性小鼠酒精诱导的运动刺激、伏隔核多巴胺释放和条件位置偏爱。

关键数值与推荐

  • 短效和长效GLP-1R激动剂已被批准用于2型糖尿病和/或肥胖。

临床怎么用

  • 提示GLP-1R激动剂可能成为AUD治疗选项,但需考虑胃排空改变、恶心和应激增强等混杂因素。

局限性

  • 证据来自临床前研究,尚未在临床人群中验证。
  • 胃排空改变、恶心和应激增强等其他因素也可能贡献于观察到的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 (GLP-1) has gained attention for its broad physiological effects, and both short-acting (exenatide/exendin-4 [Ex4]) and long-acting (liraglutide, dulaglutide, semaglutide) GLP-1 receptor (GLP-1R) agonists have been approved for type 2 diabetes and/or obesity. Initial preclinical research has highlighted the role of GLP-1 and its receptor in the pathophysiology of alcohol use disorder (AUD) and their potential use in the treatment of AUD. Specifically, systemic treatment of Ex4 reduces alcohol intake, the motivation to consume alcohol, and relapse-like behavior in male animals. Similarly, alcohol consummatory behaviors are reduced in male or female animals treated with either of the long-acting GLP-1R agonists. Moreover, both short- and long-acting GLP-1R agonists consistently attenuate the rewarding properties of alcohol, as measured by locomotor stimulation, dopamine release in the nucleus accumbens, and conditioned place preference in male mice. Because alcohol consumption is largely driven by alcohol-induced reward, it is hypothesized that GLP-1R agonists attenuate the rewarding effects of alcohol, thereby decreasing alcohol intake. However, it should be emphasized that other factors, including altered gastric emptying, nausea, and enhanced stress, may also contribute to these effects. Taken together, these preclinical studies offer insight into the potential use of GLP-1R agonists in the treatment of AUD.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jerlhag E. GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies. Biol Psychiatry. 2026. PMID: 42461204. doi:10.1016/j.biopsych.2026.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。